The role of adipokines in the rapid antidepressant effects of ketamine

Molecular Psychiatry

Volumn 22, Issue 1, 2017, Pages 127-133

  Machado Vieira, R ^a   Gold, P W ^a   Luckenbaugh, D A ^a   Ballard, E D ^a   Richards, E M ^a   Henter, I D ^a   De Sousa, R T ^a   Niciu, M J ^a   Yuan, P ^a   Zarate, C A ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; KETAMINE; LEPTIN; PLACEBO; RESISTIN; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BODY MASS; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; TREATMENT RESISTANT DEPRESSION; BIPOLAR DISORDER; BLOOD; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOUBLE BLIND PROCEDURE; FORECASTING; METABOLISM; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ADIPOKINES; ADIPONECTIN; ADULT; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; FORECASTING; HUMANS; KETAMINE; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RESISTIN; TREATMENT OUTCOME;

EID: 84962050601     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2016.36     Document Type: Article

References (58)

1. Gold PW. The organization of the stress system and its dysregulation in depressive illness. Mol Psychiatry 2015; 20: 32-47.
2. Ahima RS, Lazar MA. Adipokines and the peripheral and neural control of energy balance. Mol Endocrinol 2008; 22: 1023-1031.
3. Caselli C. Role of adiponectin system in insulin resistance. Mol Genet Metab 2014; 113: 155-160.
4. Kos K, Harte AL, da Silva NF, Tonchev A, Chaldakov G, James S et al. Adiponectin and resistin in human cerebrospinal fluid and expression of adipo-nectin receptors in the human hypothalamus. J Clin Endocrinol Metab 2007; 92: 1129-1136.
5. Une K, Takei YA, Tomita N, Asamura T, Ohrui T, Furukawa K et al. Adiponectin in plasma and cerebrospinal fluid in MCI and Alzheimer's disease. Eur J Neurol 2011; 18: 1006-1009.
6. Kadowaki T, Yamauchi T, Kubota N. The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS. FEBS Lett 2008; 582: 74-80.
7. Niciu MJ, Luckenbaugh DA, Ionescu DF, Guevara S, Machado-Vieira R, Richards EM et al. Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry 2014; 75: e417-e423.
8. Kurdi MS, Theerth KA, Deva RS. Ketamine: current applications in anesthesia, pain, and critical care. Anesth Essays Res 2014; 8: 283-290.
9. Thannikary L, Naik B. Ketamine. In: Atlee JL (ed.) Complications in Anesthesia. Saunders Elsevier: Philadelphia, PA, 2007, pp 78-79.
10. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003; 278: 45021-45026.
11. Ohashi K, Yuasa D, Shibata R, Murohara T, Ouchi N. Adiponectin as a target in obesity-related inflammatory state. Endocr Metab Immune Disord Drug Targets 2015; 15: 145-150.
12. Ouchi N, Shibata R, Walsh K. Cardioprotection by adiponectin. Trends Cardiovasc Med 2006; 16: 141-146.
13. Parker-Duffen JL, Walsh K. Cardiometabolic effects of adiponectin. Best Pract Res Clin Endocrinol Metab 2014; 28: 81-91.
14. Robinson K, Prins J, Venkatesh B. Clinical review: adiponectin biology and its role in inflammation and critical illness. Crit Care 2011; 15: 221.
15. Yamauchi T, Kadowaki T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab 2013; 17: 185-196.
16. Handelsman Y, Oral EA, Bloomgarden ZT, Brown RJ, Chan JL, Einhorn D et al. The clinical approach to the detection of lipodystrophy-an AACE consensus statement. Endocr Pract 2013; 19: 107-116.
17. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-946.
18. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev 2005; 6: 13-21.
19. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007; 380: 24-30.
20. Song J, Kang SM, Kim E, Kim CH, Song HT, Lee JE. Adiponectin receptor-mediated signaling ameliorates cerebral cell damage and regulates the neurogenesis of neural stem cells at high glucose concentrations: an in vivo and in vitro study. Cell Death Dis 2015; 6: e1844.
21. Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB et al. Adiponectin acts in the brain to decrease body weight. Nat Med 2004; 10: 524-529.
22. Thundyil J, Pavlovski D, Sobey CG, Arumugam TV. Adiponectin receptor signalling in the brain. Br J Pharmacol 2012; 165: 313-327.
23. Cizza G, Nguyen VT, Eskandari F, Duan Z, Wright EC, Reynolds JC et al. Low 24-hour adiponectin and high nocturnal leptin concentrations in a case-control study of community-dwelling premenopausal women with major depressive disorder: the Premenopausal, Osteopenia/Osteoporosis, Women, Alendronate, Depression (POWER) study. J Clin Psychiatry 2010; 71: 1079-1087.
24. Weber-Hamann B, Kratzsch J, Kopf D, Lederbogen F, Gilles M, Heuser I et al. Resistin and adiponectin in major depression: the association with free cortisol and effects of antidepressant treatment. J Psychiatr Res 2007; 41: 344-350.
25. Liu J, Guo M, Zhang D, Cheng SY, Liu M, Ding J et al. Adiponectin is critical in determining susceptibility to depressive behaviors and has antidepressant-like activity. Proc Natl Acad Sci USA 2012; 24: 12248-12253.
26. Taylor VH, Macqueen GM. The role of adipokines in understanding the associations between obesity and depression. J Obes 2010; 2010; pii: 748048; doi:10.1155/2010/748048.
27. Liu J, Garza JC, Bronner J, Kim CS, Zhang W, Lu XY. Acute administration of leptin produces anxiolytic-like effects: a comparison with fluoxetine. Psychopharmacol-ogy 2010; 207: 535-545.
28. Liu J, Guo M, Zhang D, Cheng SY, Liu M, Ding J et al. Adiponectin is critical in determining susceptibility to depressive behaviors and has antidepressant-like activity. Proc Natl Acad Sci USA 2012; 109: 12248-12253.
29. Jung HS, Park KH, Cho YM, Chung SS, Cho HJ, Cho SY et al. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res 2006; 69: 76-85.
30. Qasim AN, Metkus TS, Tadesse M, Lehrke M, Restine S, Wolfe ML et al. Resistin gene variation is associated with systemic inflammation but not plasma adipo-kine levels, metabolic syndrome or coronary atherosclerosis in nondiabetic Caucasians. Clin Endocrinol 2009; 70: 698-705.
31. Pang SS, Le YY. Role of resistin in inflammation and inflammation-related diseases. Cell Mol Immunol 2006; 3: 29-34.
32. Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in mac-rophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun 2005; 334: 1092-1101.
33. De Kock M, Loix S, Lavand'homme P. Ketamine and peripheral inflammation. CNS Neurosci Ther 2013; 19: 403-410.
34. Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimaki M. Cumulative meta-analysis of interleukins 6 and 1beta, tumor necrosis factor alpha and C-reactive protein in patients with major depressive disorder. Brain Behav Immun 2015; 49: 206-215.
35. Esel E, Ozsoy S, Tutus A, Sofuoglu S, Kartalci S, Bayram F et al. Effects of antidepressant treatment and of gender on serum leptin levels in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 565-570.
36. Zupancic ML, Mahajan A. Leptin as a neuroactive agent. Psychosom Med 2011; 73: 407-414.
37. Lu XY, Kim CS, Frazer A, Zhang W. Leptin: a potential novel antidepressant. Proc Natl Acad Sci USA 2006; 103: 1593-1598.
38. Eikelis N, Esler M, Barton D, Dawood T, Wiesner G, Lambert G. Reduced brain leptin in patients with major depressive disorder and in suicide victims. Mol Psychiatry 2006; 11: 800-801.
39. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000; 100: 197-207.
40. Stieg MR, Sievers C, Farr O, Stalla GK, Mantzoros CS. Leptin: a hormone linking activation of neuroendocrine axes with neuropathology. Psychoneuroendocrinol-ogy 2015; 51: 47-57.
41. Guo M, Lu Y, Garza JC, Li Y, Chua SC, Zhang W et al. Forebrain glutamatergic neurons mediate leptin action on depression-like behaviors and synaptic depression. Transl Psychiatry 2012; 2: e83.
42. Wysokinski A, Strzelecki D, Kloszewska I. Levels of triglycerides, cholesterol, LDL, HDL and glucose in patients with schizophrenia, unipolar depression and bipolar disorder. Diabetes Metab Syndr 2015; 9: 168-176.
43. Khan A, Leventhal RM, Khan SR, Brown WA. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 2002; 22: 40-45.
44. DiazGranados N, Ibrahim L, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010; 71: 1605-1611.
45. Zarate CA Jr., Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012; 71: 939-946.
46. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry 2001; 62: 10-17.
47. Machado-Vieira R, Yuan P, Brutsche N, DiazGranados N, Luckenbaugh D, Manji HK et al. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry 2009; 70: 1662-1666.
48. Haq AU, Sitzmann AF, Goldman ML, Maixner DF, Mickey BJ. Response of depression to electroconvulsive therapy: a meta-analysis of clinical predictors. J Clin Psychiatry 2015; 76: 1374-1384.
49. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003; 108: 736-740.
50. Owecki M, Miczke A, Nikisch E, Pupek-Musialik D, Sowinski J. Serum resistin concentrations are higher in human obesity but independent from insulin resistance. Exp Clin Endocrinol Diabetes 2011; 119: 117-121.
51. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867.
52. Burnett MS, Lee CW, Kinnaird TD, Stabile E, Durrani S, Dullum MK et al. The potential role of resistin in atherogenesis. Atherosclerosis 2005; 182: 241-248.
53. Eikelis N, Schlaich M, Aggarwal A, Kaye D, Esler M. Interactions between leptin and the human sympathetic nervous system. Hypertension 2003; 41: 1072-1079.
54. Konrad A, Lehrke M, Schachinger V, Seibold F, Stark R, Ochsenkuhn T et al. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol 2007; 19: 1070-1074.
55. Migita K, Maeda Y, Miyashita T, Kimura H, Nakamura M, Ishibashi H et al. The serum levels of resistin in rheumatoid arthritis patients. Clin Exp Rheumatol 2006; 24: 698-701.
56. Gold PW, Chrouso GP. Melancholic and atypical subtypes of depression represent distinct pathophysiological entities: CRH, neural circuits, and the diathesis for anxiety and depression. Mol Psychiatry 2013; 18: 632-634.
57. Benomar Y, Gertler A, De Lacy P, Crepin D, Ould Hamouda H, Riffault L et al. Central resistin overexposure induces insulin resistance through toll-like receptor 4. Diabetes 2013; 62: 102-114.
58. Lehto SM, Huotari A, Niskanen L, Tolmunen T, Koivumaa-Honkanen H, Honkalampi K et al. Serum adiponectin and resistin levels in major deprssive disorder. Acta Psychiatr Scand 2010; 121: 209-215.